Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy
Executive Summary
Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.
You may also be interested in...
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
FTC Wades Into ‘Rebate Walls’ And Biosimilar Access With Remicade Investigation
Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.
US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches
Amgen and Allergan’s launch of the first biosimilars to Roche/Genentech’s Avastin and Herceptin may not face the same commercial dynamics that have stymied biosimilars in other therapeutic areas, but uptake could depend upon oncologists’ comfort level in prescribing the follow-on agents.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
